Progyny patients undergoing assisted reproductive technology experience better clinical fertility outcomes across six national benchmarks.

In a pilot of obesity care, Connecticut saved as much as 3% on medication spending, based on rejecting claims and switching members to lower net cost therapies.

Amid the development of new cell and gene therapies, we present some strategies that states have used to control costs and risk among their MCOs.

We examine the impact of anti-obesity medication coverage in the Medicaid and commercial markets, as drugs such as Wegovy and Zepbound take off.

Accelerated approval drug utilizers in Medicaid are more likely to be older, with a higher proportion of Black and Asian beneficiaries, according to T-MSIS data.

Milliman partnered with the PharmAccess Foundation on an analysis involving the establishment of a health insurance pricing scheme in Africa.